Four hundred ninety-nine methicillin-resistant
Nosocomial infections due to multidrug-resistant Staphylococcus aureus are an important health problem worldwide. Antimicrobial resistance prolongs the duration of hospitalization, thereby increasing the cost of patient care.
The Center for Molecular Epidemiology and International Network of Hospitals (CEM/NET) has been created to keep track of the movement and to identify reservoirs of major multidrug-resistant clones of S. aureus and other gram-positive pathogens (10, 38) . This initiative involved a collaborative network with hospitals and health institutions of several countries that reported relatively high levels of multidrug-resistant bacteria in Europe, North America, Latin America, and Asia. Clinical isolates of methicillin-resistant S. aureus (MRSA) have been provided by collaborating national centers and deposited at two central microbiology laboratories -the Laboratory of Molecular Genetics located at the Instituto de Tecnologia Química e Biológica da Universidade Nova de Lisboa (ITQB/ UNL), Oeiras, Portugal, and the Laboratory of Microbiology of the Rockefeller University-for quality control and for testing by microbiological and molecular typing techniques. Such studies have identified some internationally spread MRSA clones, i.e., the Iberian (12, 33) , Brazilian (35) , Pediatric (29) , and New York-Tokyo clones (1, 26) .
The SENTRY Antimicrobial Surveillance Program, another private network that monitors the frequency of occurrence and antimicrobial susceptibility of predominant pathogens causing infections worldwide, conducted several studies during 1997 and 1998 in Latin America (Argentina, Brazil, Chile, Colombia, Mexico, Uruguay, and Venezuela). These surveillance studies have reported a high occurrence of MRSA for commonly observed infections in this geographic region. (i) A survey of bloodstream infections carried out in 1997 showed that 21% of the 1,642 infections were attributable to S. aureus, out of which 29% were resistant to oxacillin (24) . (ii) In the same year, another survey of lower respiratory tract infection of hospitalized patients with pneumonia revealed that 23% of 556 isolates collected were identified as S. aureus and resistance to oxacillin was detected in nearly 50% of these isolates (27) . (iii) During 1997 and 1998, S. aureus was found as the most common (31%) etiologic agent among 885 bacterial isolates responsible for skin and soft tissue infections and 31% of the isolates were MRSA (14) . Moreover, oxacillin resistance among S. aureus isolated from patients with bloodstream in-fections increased approximately 5% in Latin America over the 1-year period from 1997 to 1998 (11) .
In a more recent study performed under the CEM/NET Initiative, Project RESIST, we have shown that marked geographic variation in multiresistance patterns exist among MRSA isolated in 6 countries of South America (Colombia, Argentina, Brazil, Chile, Mexico, and Uruguay) (32) .
The molecular typing performed with the MRSA strains from Colombia has been previously reported (15) . The aim of the present study was to assess the current MRSA clonal types responsible for nosocomial infection in 22 medical centers of the other five Latin American countries: Argentina, Brazil, Chile, Mexico, and Uruguay.
MATERIALS AND METHODS
Participating institutions. Twenty-two clinical institutions from five Latin American countries-Argentina, Brazil, Chile, Uruguay, and Mexico-participated in this study. The institutions provided isolates recovered in different periods of isolation, 1, 2, or 3 years, within the period from 1996 to 1998. The names and locations of the hospitals included in this study, their specialty, their size, the number of strains recovered from each institution, and the year of collection are listed in Table 1 .
Bacterial isolates. A total of 499 isolates previously identified as MRSA by the collaborating centers-28 from Mexico, 89 from Argentina, 102 from Uruguay, 118 from Chile, and 162 from Brazil-collected during a 3-year period (1996 to 1998) were analyzed in this study. A common specimen sheet with information concerning the origin of each isolate was provided by the collecting centers. The information included not only demographic data, such as patient name, gender, date of birth, immunodeficiency, origin (nosocomial or community), clinical service, and hospitalization in intensive care unit (ICU) but also specimen data such as the date of collection and the source. The majority of the isolates (81%) were responsible for infection, and all were consecutively recovered from single patients from various sources: 35% from respiratory sources, 25% from wound, 25% from blood, 8% from abscess, 2% from urine, and 5% from other nonspecified sources. The Mexican isolates were mainly from blood (57%), while the Chilean isolates were predominantly from wounds (52%). All isolates were identified at the collaborating institutions and sent to the central laboratory, i.e., the Laboratory of Molecular Genetics located at Instituto de Technologia Química e Biológica da Universidade Nova de Lisboa (ITQB/UNL), Oeiras, Portugal, for pheno-and genotypic characterization.
Demographic information. Globally, 51% of the isolates were recovered from adults, 29% from elderly individuals (over 65 years old), and 20% from children (under 12 years old). However, hospitals from Mexico and Argentina provided predominantly isolates from children (100 and 44%, respectively), in contrast to Uruguay and Brazil, where only 3 and 7% of the isolates were from patients under 12 years old. The great majority of the isolates (85%) were recovered from inpatients hospitalized for more than 48 h, out of which 44% were in ICUs. The patients were hospitalized or treated in different clinical services: 48% in medicine, 25% in surgery, 17% in pediatrics, 1% in gynecology, and 9% in other services. Eleven percent of the isolates were from immunocompromized patients.
Control strains. S. aureus ATCC 25923 and Escherichia coli ATCC 25922 were included in the assays for quality control of susceptibility testing. The partially dalfopristin-and quinupristin-resistant S. aureus clinical isolates Syn1 and Syn25 (provided by Rhône-Poulenc Rorer, S.A.) were included as quality control strains in the determination of dalfopristin-quinupristin susceptibility testing. S. aureus ATCC 29213 and S. aureus PC3 (34) were used as controls in the vancomycin resistance screen assay. Reference strains for ClaI-mecA and Tn554 patterns and representative strains used to compare the pulsed-field gel electrophoresis (PFGE) profiles were from the MRSA strain collection of the Laboratory of Molecular Genetics at ITQB/UNL. Control strains for ClaI-mecA patterns were HPV107 (pattern I) (33), BK71 (II), RN7164 (III), RN6322 (V) (17) , PER168 (IX) (12) , HU25 (XI) (2, 35) , and PL48 (XX) (18) . Control strains for ClaI-Tn554 patterns were RN7178 (pattern A), BK798 (AA), RN7174 (B), RN7538 (M) (17), HPV107 (E) (33), POL2 () (18) , and ITA33 () (19) . Control Antimicrobial susceptibility testing. Susceptibility to 12 antimicrobial agents (penicillin, oxacillin, trimethoprim-sulfamethoxazole, ciprofloxacin, chloramphenicol, clindamycin, erythromycin, gentamicin, rifampin, tetracycline, vancomycin, and teicoplanin; Oxoid, Basingstoke, Hampshire, England) was confirmed at the central laboratory by disk diffusion according to the National Committee for Clinical Laboratory Standards guidelines (21) . Susceptibility to dalfopristinquinupristin (provided by Rhône-Poulenc Rorer, S.A.) was evaluated by the agar dilution technique as previously described (32) .
Expression of oxacillin resistance. The mode of expression of oxacillin resistance was tested by population analysis profiles (PAPs) by using cultures grown overnight in tryptic soy broth (Difco, Oxoid, Hampshire, United Kingdom) (8, 9) . Twenty isolates representative of the three major clonal types found in this study were tested. Strains were assigned to phenotypic expression classes on the basis of the oxacillin MIC that was arbitrarily defined as the lowest concentration of the antibiotic that prevented the appearance of 99.9% of bacterial colonies (39) .
Vancomycin agar screen. Detection of vancomycin-resistant S. aureus (VRSA) strains was done by vancomycin agar screen. A suspension of cells from a 20-to 24-h tryptic soy agar plate (Difco) was prepared in sterile water to a turbidity equivalent to that of 0. (17), (18), BЈ (7), and (19) were previously described. Patterns EЈ, , MM, NN, OO, PP, and QQ correspond to novel patterns described in this study. were plated onto Mueller-Hinton agar (MH; Difco) containing 2 g of vancomycin per ml. Growth was recorded following 24 and 48 h of incubation at 35°C. A reduction of the vancomycin concentration to 2 g/ml (37) and an incubation time of 48 h decrease the likelihood of not detecting VRSA strains. The MIC was subsequently evaluated by E-test (AB Biodisk, Solne, Sweden) according to manufacturer's instructions for all strains that presented growth of at least one colony. The E-test was performed in MH with an incubation for 24 h at 35°C.
DNA probes, mecA-Tn554 polymorphisms, and PFGE. Protocols for DNA probes (mecA, mecI, and Tn554), preparation and labeling for ClaI::mecA and ClaI::Tn554 patterns, as well as PFGE were performed as previously reported (3, 5, 8, 17) . PFGE patterns were compared by visual inspection (36), followed by computer analysis using Whole Band Analyzer version 3.3 (BioImage, Ann Arbor, Mich.) software for UNIX SparcStation 4 running under SunOS version 5.5.1 operating systems (26) .
RESULTS

MRSA clonal classification.
Strains were classified into clonal types on the basis of a combination of their particular mecA and Tn554 polymorphisms and PFGE patterns (mecA::Tn554::PFGE types). In addition, the sequences of mecA, mecl, and Tn554 were located in the bacterial chromosome (see below).
Analysis of the mecA vicinity and Tn554 insertion patterns and PFGE patterns distributed 494 MRSA isolates into nine different mecA polymorphs, 17 Tn554 patterns, and 11 PFGE patterns. However, mecA polymorph XI (12), its variants III and IX (12), Tn554 type B (17), or its relative BЈ (7), and PFGE pattern B were clearly predominant, representing 78, 62, and 79% of the isolates, respectively. Of the 499 isolates, 5 were found not to carry the mecA gene when analyzed at the central laboratory (see below). Figures 1 and 2A show the ClaI-Tn554 patterns identified among the Latin American strains and the PFGE patterns representing the three major clonal types found in this MRSA collection.
PFGE pattern B was predominant in all countries, except Mexico, showing between 13 (Chile) and 30 subtypes (Brazil). Although PFGE type B was generally associated with ClaImecA polymorph XI (or its variants III and IX), it was related to different ClaI-Tn554 patterns, and this feature was characteristic of isolates of a given country. In fact, PFGE type B was mainly associated with Tn554 patterns B in Brazil and B or BЈ in Argentina and Uruguay and with pattern (18) in Chile. The PFGE analysis also identified two other important fingerprints: pattern F (11%) found in Chile associated with ClaImecA polymorph II (17) and Tn554 pattern EЈ (corresponding to a small variation of pattern E [17] ) and PFGE pattern M The characteristic antibiotype is indicated for the major clones: P, penicillin; O, oxacillin; Sxt, trimethoprim-sulfamethoxazole; Ci, ciprofloxacin; C, chloramphenicol; Cl, clindamycin; E, erythromycin; G, gentamicin; R, rifampin; T, tetracycline; QD, quinupristin-dalfopristin; V, vancomycin; T, teicoplanin. Superscripts: R, resistant; S, susceptible.
b ClaI-mecA patterns I, II, III, V (17), IX, XI (12) , and XX (18) were previously described. Pattern IX corresponds to a small variation of pattern IX. ClaI-Tn554 patterns A, B, AA, M (17), BЈ (7), (18) , and (19) were previously described. NH, no homology. Patterns , MM, NN, OO, PP, and QQ correspond to novel patterns. Pattern EЈ corresponds to a small variation of pattern E (17) .
c An exception is considered when at least 50% of the isolates show a different susceptibility pattern relative to the characteristic antibiotype.
(6%) characteristic of all isolates collected in Mexico with no homology to Tn554 and associated with ClaI-mecA polymorph I (17) . Although the 494 MRSA isolates were distributed into 39 clones, three major clonal families were noticeable (see Table  2 ). The first lineage was found with an indubitable preponderance (79%) and was represented by the Brazilian clone (XI::B::B) and its closely relatives having variable mecA or Tn554 patterns but similar PFGE profiles: XI::BЈ::B, III::B::B, III::BЈ::B, XI::::B, and III::::B. This lineage was clearly dominant in Uruguay (100%), Brazil (97%), and Argentina (86%) and represented approximately half of the isolates from Chile (53%). The remaining isolates of Chile (47%) belonged to the second family, the Chilean clone (II::EЈ::F). The third important and unique lineage was the Mexican clone (I::NH::M) that included all the isolates recovered at one pediatric hospital from Mexico.
Characteristics of the major MRSA clones. (i) Resistance to antimicrobial agents. The resistance profile of each major clonal type is shown in Table 2 . The Brazilian clone (XI::B::B and its relatives) was resistant to penicillin (100%), oxacillin (99%), trimethoprim-sulfamethoxazole (99%), ciprofloxacin (98%), chloramphenicol (79%), clindamycin (97%), erythromycin (99%), gentamicin (92%), rifampin (53%), and tetracycline (98%). Interestingly, all strains from Uruguay related to this clonal type were susceptible to rifampin. Strains from Chile belonging to clone II::EЈ::F or its variants were resistant to penicillin (100%), oxacillin (100%), ciprofloxacin (100%), chloramphenicol (70%), clindamycin (98%), erythromycin (98%), and gentamicin (98%). Strains of the Mexican clone (I::NH::M) were only resistant to penicillin (100%), oxacillin (100%), and gentamicin (79%). All 494 isolates were susceptible to teicoplanin, vancomycin, and dalfopristin-quinupristin. Of the 499 strains screened for VRSA, 37 isolates exhibited growth at 2 g of vancomycin per milliliter after 48 h (between 1 and ca. 100 colonies). However, the vancomycin MICs ranged from 1 to 2 g/ml. The three major clonal families could be distinguished by the mode of oxacillin expression: the Brazilian clone showed high-level resistance (MIC ϭ 400 g/ ml) and homogeneous expression class 4, the Chilean clone showed intermediate profile (MIC ϭ 100 g/ml) and heterogeneous expression class 3, and the Mexican clone showed low-level resistance (MIC ϭ 12 g/ml) and also heterogeneous phenotype class 2. Isolates belonging to the Mexican clone do not grow at concentrations of Ͼ25g/ml, and isolates belonging to the Chilean clone do not grow at concentrations of Ͼ800 g/ml (data not shown).
( Five S. aureus strains collected in hospital 2 in Buenos Aires, Argentina, initially classified by the collaborating institution as MRSA, did not hybridize with the mecA (Fig. 2B) nor the mecI probes (result not shown) and displayed susceptibility to oxacillin when the antibiogram and the molecular typing were performed at the central laboratory. However, these five strains had a multiresistant antibiotype: they showed resistance to penicillin, trimethoprim-sulfamethoxazole, ciprofloxacin, erythromycin, gentamicin, rifampin, tetracycline, clindamycin, and chloramphenicol (three isolates). Interestingly, these isolates have PFGE patterns similar to the PFGE pattern B characteristic of the Brazilian clone ( Fig. 2A) and carried one (pattern E, four isolates) or two copies (pattern AA, one isolate) of Tn554 (Fig. 2C) .
MRSA clonal evolution in Latin American hospitals during 1996 to 1998. Figure 3 represents the major clonal types found in each country in two periods of time: 1996 to 1997 and 1998. In Argentina, Brazil, Chile, and Mexico there was no significant difference in the frequency of the major clonal types in both periods. In contrast, in Uruguay, during 1996 to 1997, clonal type XI::BЈ::B and its variant associated with Tn554 pattern BЈ (III::BЈ::B) represented more than half of the isolates (68%), whereas clone XI::B::B and its variants associated with Tn554 pattern B (IX::B::B and III::B::B) represented only 32%. In 1998 this last clone represented almost all isolates (91%), whereas clone XI::BЈ::B was reduced to 9%.
Geographic dissemination of clonal types. PFGE patterns B, F, and M, characteristic of, respectively, the Brazilian, the Chilean, and the Mexican MRSA clones were compared with representative PFGE patterns of other MRSA strains stored in the CEM/NET database. PFGE type B found in Brazil, Argentina, Uruguay, and Chile showed a high degree of similarity with the prototype of the MRSA Brazilian clone (35) (Fig. 2A) . PFGE type M from Mexico was found to be closely related to a representative of the dominant clone in 1993 and 1998 of a hospital in Patras, Greece (I. Spiliopoulou et al., unpublished), while type F from Chile had no resemblance to any other profiles of MRSA clones found so far (Fig. 4) .
DISCUSSION
In this work, a collection of 494 MRSA isolates was analyzed by applying the same set of molecular typing methods used in other MRSA typing studies performed in our laboratory. Interestingly, only a few clonal types were found among these large collections of isolates recovered in 1996 to 1998 from five different countries of Latin America (Argentina, Brazil, Chile, Uruguay, and Mexico).
The Brazilian multiresistant clonal type (XI::B::B), together with its relatives, represented 79% of the 494 MRSA isolates. Previous studies documented the preponderance and extensive geographic spread in Brazil of a unique MRSA clone XI::B::B. This multiresistant and epidemic clone was reported as the most frequent among MRSA isolates recovered from several hospitals in seven cities located in the Northern as well as in the Southern parts of the country and separated by a distance of several thousand of kilometers from one another (13, 25, 28, 30, 31, 35) . Our study reports the predominance (97%) and persistence of clone XI::B::B in Brazil among isolates from 1996 to 1998. This clone has been maintained in the country for a considerable period, at least since 1990 (28) , which may explain the large variability associated with PFGE (30 subtypes).
Previous studies have reported the spread of the Brazilian clone to three different cities of Argentina (Buenos Aires, Posadas, and San Miguel de Tucumán) separated by a distance of over 1,000 km from one another (4, 6) . Our study confirms the predominance (86%) of the Brazilian clone in 1996 to 1998 in three hospitals of Buenos Aires.
Impressively, the Brazilian clone was the unique clonal type present in Uruguay; clonal type XI::B::B and its variants (III::B::B, IX::B::B, III::BЈ::B, and XI::BЈ::B) represented all isolates recovered from 1996 to 1998 in this country, confirming the capacity of spread and high epidemicity of this MRSA clone.
A variant of the Brazilian clone (XI::::B), which contains a different Tn554 type (pattern ), was detected with a frequency of 53% in Chile during 1997 to 1998. Recently, Gales et al. (14) reported an identical observation, among multidrug-resistant MRSA collected during 1997 to 1998 in Brazil, Chile, and Argentina which exhibited an identical ribotype and similar SmaI PFGE pattern to a representative of the Brazilian MRSA clone. Besides the ability to acquire new genes, including highlevel mupirocin resistance (25) , the Brazilian clone seems to spread alarmingly fast and have a great capacity for displacement of other very epidemic clones, as seen in Portugal (2, 23) and the Czech Republic (20) .
Our study clearly documents the massive dissemination of the Brazilian clone in four countries of South America, Brazil, Argentina, Uruguay, and Chile, all sharing directly or indirectly national borders. The presence of this clone in Mexican hospitals cannot be excluded since we have analyzed MRSA isolates exclusively from one Mexican pediatric hospital.
In contrast to the recent report of emergence of a vancomycin and teicoplanin heterogeneously resistant subpopulation among MRSA isolates belonging to the Brazilian clone widely spread in a hospital in the Northeast region of Brazil (13) , no VRSA or hetero-VRSA strains have been found among our collection of 499 isolates from Latin America. These strains may be rare, which means it is necessary to continue the surveillance for this phenotype.
Identification of five methicillin-susceptible S. aureus strains with a relatively high drug resistance profile, Tn554 insertions, and PFGE type similar to the PFGE pattern B suggests that they were probably derived from the Brazilian clone by deletion of mecA and mecI. Moreover, four of these strains lack the two Tn554 insertions located in the usual SmaI fragments of mecA (119 or 95 kb), suggesting the loss of these copies of the transposon together with the mecA gene. Recently, two cassette chromosome recombinase genes (ccrA and ccrB) were found to catalyze excision of the 52-kb staphylococcal cassette chromosome mec (16) . However, we cannot exclude the hypothesis that these MSSA strains (or strains with a similar background) may be a progenitor to the Brazilian clone.
Clonal type II::EЈ::F was highly represented in Chile (47%) in coexistence with the Brazilian clone and designated as the Chilean MRSA clone for being exclusively identified in this country so far. The Chilean and the Brazilian clones were represented by similar percentages during 1997 and 1998 (47 versus 53%), which might signify that clone II::EЈ::F is as epidemic as the Brazilian clone. It would be interesting to monitor the evolution of these two clones in isolates from 1999 to 2000 not only in Chile but also in other countries of South America.
Comparative analysis of MRSA from different geographic origins revealed a high degree of similarity between the single clonal type found in Mexico, designated the Mexican clone (I::NH::M), and the predominant clone found among samples of 1993 and 1998 in a hospital in Patras, Greece (I. Spiliopoulou et al, unpublished). This is probably one more example of the long-distance capacity of spread of certain MRSA clones. Clonal type I::NH::M was found in Mexico among strains recovered from a single hospital and had a relatively limited drug resistance profile; strains showed resistance to penicillin, oxacillin, and gentamicin only and belonged to the phenotypic oxacillin expression class 2 (MIC ϭ 12 g/ml), which may be explained by its pediatric origin. Isolates belonging to the Pediatric MRSA clone were found to lack Tn554 transposon, belong to oxacillin expression class 1 or 2, and show lowerresistance phenotypes, which are probably related to the antibiotic policy practiced in pediatric settings (29) .
Among strains belonging to the Brazilian, the Chilean, and the Mexican clones, only representatives of the Brazilian clone had homology with the mecI gene. Strains belonging to the Pediatric MRSA clone (29) , as well as historically early MRSA isolates belonging to the Archaic clone (7), were found to lack sequences that hybridize with mecI. We might speculate that the Chilean and Mexican clones represent chronologically old MRSA clones that survived into the contemporary era.
There is no considerable difference between both periods (1996 to 97 and 1998) except for Uruguay, where clonal types associated with the Tn554 pattern BЈ tended to decrease relative to clones associated with Tn554 pattern B. This fact was not observed in other countries, and the reason for this remains unclear. A great number of variants of the major clonal types were predominantly found in larger hospitals, elderly patients, patients not immunocompromized, and patients interned in the Medicine service, which may be related to a long period of hospitalization.
This study provides a perspective on the increasing uniformity of the MRSA clones in South America, which seems to be due to the continued geographic spread of a relative few very epidemic strains among hospitals, across national boundaries and across continents.
